Regorafenib A Multi-Kinase Inhibitor for Refractory Cancers – Mechanism, Clinical Applications, and Emerging Insights Introduction Regorafenib is an orally administered multikinase inhibitor used in the treatment of various refractory cancers. Approved by the U.S. FDA in 2012, it offers a new line […]